Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to identify cells responsible for intrahepatic Soluble Fas ligand (FasL) expression to evaluate which cell types may contribute to liver damage in patients started treatment with tenofovir alafenamide

Next Previous
X
Search
Trial Profile

A study to identify cells responsible for intrahepatic Soluble Fas ligand (FasL) expression to evaluate which cell types may contribute to liver damage in patients started treatment with tenofovir alafenamide

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir alafenamide (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics

    • Most Recent Events

    • 18 Aug 2021 New trial record
    • 26 Jun 2021 Results presented at The International Liver Congress 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top